Institut für Pharmakologie und Klinische Pharmakologie, Klinikum der Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany.
Mol Pharmacol. 2011 Aug;80(2):337-44. doi: 10.1124/mol.111.072850. Epub 2011 May 19.
Thrombin promotes vascular smooth muscle cell (SMC) proliferation and inflammation via protease-activated receptor (PAR)-1. A further thrombin receptor, PAR-3, acts as a PAR-1 cofactor in some cell-types. Unlike PAR-1, PAR-3 is dynamically regulated at the mRNA level in thrombin-stimulated SMC. This study investigated the mechanisms controlling PAR-3 expression. In human vascular SMC, PAR-3 siRNA attenuated thrombin-stimulated interleukin-6 expression and extracellular signal-regulated kinases 1/2 phosphorylation, indicating PAR-3 contributes to net thrombin responses in these cells. Thrombin slowed the decay of PAR-3 but not PAR-1 mRNA in the presence of actinomycin D and induced cytosolic shuttling and PAR-3 mRNA binding of the mRNA-stabilizing protein human antigen R (HuR). HuR siRNA prevented thrombin-induced PAR-3 expression. By contrast, forskolin inhibited HuR shuttling and destabilized PAR-3 mRNA, thus reducing PAR-3 mRNA and protein expression. Other cAMP-elevating agents, including the prostacyclin-mimetic iloprost, also down-regulated PAR-3, accompanied by decreased HuR/PAR-3 mRNA binding. Iloprost-induced suppression of PAR-3 was reversed with a myristoylated inhibitor of protein kinase A and mimicked by phorbol ester, an inducer of cyclooxygenase-2. In separate studies, iloprost attenuated PAR-3 promoter activity and prevented binding of nuclear factor of activated T cells (NFAT2) to the human PAR-3 promoter in a chromatin immunoprecipitation assay. Accordingly, PAR-3 expression was suppressed by the NFAT inhibitor cyclosporine A or NFAT2 siRNA. Thus human PAR-3, unlike PAR-1, is regulated post-transcriptionally via the mRNA-stabilizing factor HuR, whereas transcriptional control involves NFAT2. Through modulation of PAR-3 expression, prostacyclin and NFAT inhibitors may limit proliferative and inflammatory responses to thrombin after vessel injury.
凝血酶通过蛋白酶激活受体(PAR)-1 促进血管平滑肌细胞(SMC)增殖和炎症。另一种凝血酶受体 PAR-3 在某些细胞类型中作为 PAR-1 的共受体发挥作用。与 PAR-1 不同,PAR-3 在凝血酶刺激的 SMC 中在 mRNA 水平上受到动态调节。本研究探讨了控制 PAR-3 表达的机制。在人血管 SMC 中,PAR-3 siRNA 减弱了凝血酶刺激的白细胞介素-6 表达和细胞外信号调节激酶 1/2 磷酸化,表明 PAR-3 有助于这些细胞中的净凝血酶反应。凝血酶在放线菌素 D 存在下减缓 PAR-3 但不减缓 PAR-1 mRNA 的衰减,并诱导细胞质易位和 mRNA 稳定蛋白人抗原 R(HuR)与 PAR-3 mRNA 的结合。HuR siRNA 阻止了凝血酶诱导的 PAR-3 表达。相比之下,福司可林抑制 HuR 易位并使 PAR-3 mRNA 不稳定,从而减少 PAR-3 mRNA 和蛋白表达。其他升高 cAMP 的试剂,包括前列环素类似物依洛前列素,也下调了 PAR-3,同时 HuR/PAR-3 mRNA 结合减少。用蛋白激酶 A 的豆蔻酰化抑制剂逆转了依洛前列素诱导的 PAR-3 抑制,并通过诱导环氧化酶-2 的佛波酯模拟。在单独的研究中,依洛前列素在染色质免疫沉淀测定中减弱了 PAR-3 启动子活性并阻止了激活 T 细胞的核因子(NFAT)2 与人类 PAR-3 启动子的结合。因此,PAR-3 表达被 NFAT 抑制剂环孢素 A 或 NFAT2 siRNA 抑制。因此,与 PAR-1 不同,人类 PAR-3 通过 mRNA 稳定因子 HuR 进行转录后调节,而转录控制涉及 NFAT2。通过调节 PAR-3 表达,前列环素和 NFAT 抑制剂可能会限制血管损伤后对凝血酶的增殖和炎症反应。